Pictet Asset Management Sa I Mab Transaction History

Pictet Asset Management Sa

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$3.22 - $4.86 $39,284 - $59,292	12,200 New	12,200 $51,000
Q2 2022 Aug 09, 2022	SELL	$8.27 - $18.43 $2.72 Million - $6.05 Million	-328,376 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$12.54 - $46.93 $8.73 Million - $32.7 Million	-695,825 Reduced 67.94%	328,376 $5.33 Million
Q4 2021 Feb 10, 2022	BUY	$45.28 - $74.5 $4.22 Million - $6.94 Million	93,184 Added 10.01%	1,024,201 $48.5 Million
Q3 2021 Nov 12, 2021	BUY	$57.18 - $84.43 $53.2 Million - $78.6 Million	931,017 New	931,017 $67.5 Million

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $78.9M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Pictet Asset Management Sa, based on Form 13F filings with the SEC.

Stay updated on Pictet Asset Management Sa with notifications on news.